Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Inventory: 2023-2025

Historic Inventory for Tg Therapeutics (TGTX) over the last 3 years, with Sep 2025 value amounting to $147.0 million.

  • Tg Therapeutics' Inventory rose 73.56% to $147.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.0 million, marking a year-over-year increase of 73.56%. This contributed to the annual value of $110.5 million for FY2024, which is 177.37% up from last year.
  • Tg Therapeutics' Inventory amounted to $147.0 million in Q3 2025, which was down 5.32% from $155.2 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Inventory high stood at $157.8 million for Q1 2025, and its period low was $27.2 million during Q1 2023.
  • Its 3-year average for Inventory is $85.9 million, with a median of $81.2 million in 2024.
  • Data for Tg Therapeutics' Inventory shows a peak YoY skyrocketed of 185.51% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Tg Therapeutics' Inventory stood at $39.8 million in 2023, then surged by 177.37% to $110.5 million in 2024, then soared by 73.56% to $147.0 million in 2025.
  • Its Inventory stands at $147.0 million for Q3 2025, versus $155.2 million for Q2 2025 and $157.8 million for Q1 2025.